{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:52:22Z","timestamp":1790790742947,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T00:00:00Z","timestamp":1620432000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T00:00:00Z","timestamp":1620432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cytogenet"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Myelodysplastic syndrome (MDS), a heterogeneous group of hematopoietic malignancy, has been shown to present different cytogenetic abnormalities, risk factors, and clinico-hematological features in different populations and geographic areas. Herein, we determined the cytogenetic spectrum and clinico-hematological features of Iranian MDS patients for the first time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This prospective cross-sectional study was conducted on 103 patients with MDS in Ahvaz, southwest of Iran, from 2014 to 2018. Clinical presentations, complete blood counts (CBC), and bone marrow (BM) biopsy samples were assessed. Perls' staining was used to evaluate BM iron storage. The cytogenetic evaluation was performed using the conventional G banding method on the BM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients\u2019 median age was 62.3 (ranged from 50\u201376), and the majority were male (72.8%). The most common clinical symptom at the time of admission was fatigue (n\u2009=\u200933) followed by pallor (n\u2009=\u200927). The most common subgroup was MDS-Multi Lineage Dysplasia (MDS-MLD) (n\u2009=\u200938, 36.8%), followed by MDS-Single Lineage Dysplasia (MDS-SLD) (n\u2009=\u200928, 18.4%). A normal karyotype was observed in 59 patients (57.3%), while 44 patients (42.7%) had cytogenetic abnormalities. Trisomy 8 (+\u20098) was the most common cytogenetic abnormality (n\u2009=\u200914) followed by del 17p (n\u2009=\u20099) and monosomy 7 (\u2212\u20097) (n\u2009=\u20097). Twelve patients (11.65%) were transformed to AML.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our data betokened that among our MDS patients, Trisomy 8 is the predominant cytogenetic abnormality, and MDS-MLD and MDS-SLD are the most common of subtypes. Noteworthy, the male: female ratio was slightly higher in Iran than in previous reports from other parts of the world. Our study is the first report of the clinical, hematological, and cytogenetic spectrum of MDS patients in Iran<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13039-021-00548-z","type":"journal-article","created":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T09:03:07Z","timestamp":1620464587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinico-Hematological and cytogenetic spectrum of adult myelodysplastic syndrome: The first retrospective cross-sectional study in Iranian patients"],"prefix":"10.1186","volume":"14","author":[{"given":"Mostafa","family":"Paridar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazem","family":"Zibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Esmaeil","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Khosravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maral","family":"Soleymani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebrahim","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8939-491X","authenticated-orcid":false,"given":"Omid Kiani","family":"Ghalesardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,8]]},"reference":[{"issue":"2","key":"548_CR1","first-page":"311","volume":"10","author":"S Shahrabi","year":"2016","unstructured":"Shahrabi S, Khosravi A, Shahjahani M, Rahim F, Saki N. Genetics and epigenetics of myelodysplastic syndromes and response to drug therapy: new insights. Oncol Rev. 2016;10(2):311.","journal-title":"Oncol Rev"},{"issue":"3","key":"548_CR2","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/ejh.13092","volume":"101","author":"RM Shallis","year":"2018","unstructured":"Shallis RM, Ahmad R, Zeidan AM. The genetic and molecular pathogenesis of myelodysplastic syndromes. Eur J Haematol. 2018;101(3):260\u201371.","journal-title":"Eur J Haematol"},{"issue":"17","key":"548_CR3","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1200\/JCO.2009.25.2395","volume":"28","author":"SL Goldberg","year":"2010","unstructured":"Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(17):2847\u201352.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"7 Suppl","key":"548_CR4","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.amjmed.2012.04.014","volume":"125","author":"X Ma","year":"2012","unstructured":"Ma X. Epidemiology of myelodysplastic syndromes. Am J Med. 2012;125(7 Suppl):S2-5.","journal-title":"Am J Med"},{"issue":"1","key":"548_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/ajh.24930","volume":"93","author":"G Montalban-Bravo","year":"2018","unstructured":"Montalban-Bravo G, Garcia-Manero G. Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management. Am J Hematol. 2018;93(1):129\u201347.","journal-title":"Am J Hematol"},{"issue":"20","key":"548_CR6","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"2","key":"548_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.20517\/2394-4722.2016.61","volume":"3","author":"M Paridar","year":"2017","unstructured":"Paridar M, Ghalesardi OK, Seghatoleslami M, Ahmadzadeh A, Khosravi A, Saki N. Cytogenetic and molecular basis of BCR-ABL myelodysplastic syndrome: diagnosis and prognostic approach. J Cancer Metastasis Treat. 2017;3(2):38\u201344.","journal-title":"J Cancer Metastasis Treat"},{"issue":"2","key":"548_CR8","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00580-017-2602-4","volume":"27","author":"OK Ghale-sardi","year":"2018","unstructured":"Ghale-sardi OK, JalaliFar MA, Khodadi E, Ahmadzadeh A, Saki N. BCR\/ABL analysis in myelodysplastic syndromes. Comp Clin Pathol. 2018;27(2):379\u201384.","journal-title":"Comp Clin Pathol"},{"issue":"12","key":"548_CR9","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454\u201365.","journal-title":"Blood"},{"issue":"5","key":"548_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41408-018-0085-4","volume":"8","author":"DP Steensma","year":"2018","unstructured":"Steensma DP. Myelodysplastic syndromes current treatment algorithm 2018. Blood Cancer J. 2018;8(5):47.","journal-title":"Blood Cancer J"},{"issue":"12","key":"548_CR11","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1002\/cncr.23977","volume":"113","author":"O Pozdnyakova","year":"2008","unstructured":"Pozdnyakova O, Miron PM, Tang G, Walter O, Raza A, Woda B, et al. Cytogenetic abnormalities in a series of 1029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. Cancer. 2008;113(12):3331\u201340.","journal-title":"Cancer"},{"issue":"7","key":"548_CR12","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1080\/10428190701377063","volume":"48","author":"F Demirkan","year":"2007","unstructured":"Demirkan F, Alacacioglu I, Piskin O, Ozsan HG, Akinci B, Ozcan AM, et al. The clinical, haematological and morphological profile of patients with myelodysplastic syndromes: a single institution experience from Turkey. Leuk Lymphoma. 2007;48(7):1372\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"548_CR13","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1159\/000338939","volume":"35","author":"N Gattermann","year":"2012","unstructured":"Gattermann N, Kundgen A, Kellermann L, Zeffel M, Paessens B, Germing U. Diagnosis and therapy of myelodysplastic syndromes in Germany: a retrospective multicenter analysis. Onkologie. 2012;35(6):350\u20136.","journal-title":"Onkologie"},{"issue":"2","key":"548_CR14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000375149","volume":"134","author":"K Madry","year":"2015","unstructured":"Madry K, Machowicz R, Waszczuk-Gajda A, Drozd-Sokolowska J, Holowiecka BS, Wiater E, et al. Demographic, Hematologic, and clinical features of myelodysplastic syndrome patients: results from the first polish myelodysplastic syndrome registry. Acta Haematol. 2015;134(2):125\u201334.","journal-title":"Acta Haematol"},{"issue":"5","key":"548_CR15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/sj.leu.2403688","volume":"19","author":"B Chen","year":"2005","unstructured":"Chen B, Zhao WL, Jin J, Xue YQ, Cheng X, Chen XT, et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia. 2005;19(5):767\u201375.","journal-title":"Leukemia"},{"issue":"2","key":"548_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1600-0609.2004.00271.x","volume":"73","author":"T Chatterjee","year":"2004","unstructured":"Chatterjee T, Dixit A, Mohapatra M, Tyagi S, Gupta PK, Mishra P, et al. Clinical, haematological and histomorphological profile of adult myelodysplastic syndrome. Study of 96 cases in a single institute. Eur J Haematol. 2004;73(2):93\u20137.","journal-title":"Eur J Haematol"},{"issue":"5","key":"548_CR17","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s00277-004-0997-x","volume":"84","author":"AG Dakshinamurthy","year":"2005","unstructured":"Dakshinamurthy AG, Novitzky N, Bharadwaj R, Prakhya BM. Cytogenetic analysis of 52 Indian patients with de novo myelodysplastic syndromes-a comparative analysis of results with reports from Asia. Ann Hematol. 2005;84(5):298\u2013303.","journal-title":"Ann Hematol"},{"key":"548_CR18","first-page":"452","volume":"134","author":"R Chaubey","year":"2011","unstructured":"Chaubey R, Sazawal S, Dada R, Mahapatra M, Saxena R. Cytogenetic profile of Indian patients with de novo myelodysplastic syndromes. Indian J Med Res. 2011;134:452\u20137.","journal-title":"Indian J Med Res"},{"issue":"6","key":"548_CR19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2188\/jea.JE20140042","volume":"24","author":"D Chihara","year":"2014","unstructured":"Chihara D, Ito H, Katanoda K, Shibata A, Matsuda T, Sobue T, et al. Incidence of myelodysplastic syndrome in Japan. J Epidemiol. 2014;24(6):469\u201373.","journal-title":"J Epidemiol"},{"issue":"10","key":"548_CR20","doi-asserted-by":"publisher","first-page":"e110850","DOI":"10.1371\/journal.pone.0110850","volume":"9","author":"J Jin","year":"2014","unstructured":"Jin J, Yu M, Hu C, Ye L, Xie L, Jin J, et al. Pesticide exposure as a risk factor for myelodysplastic syndromes: a meta-analysis based on 1942 cases and 5359 controls. PLoS ONE. 2014;9(10):e110850.","journal-title":"PLoS ONE"},{"issue":"1","key":"548_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1476-069X-9-31","volume":"9","author":"A Khalade","year":"2010","unstructured":"Khalade A, Jaakkola MS, Pukkala E, Jaakkola JJ. Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis. Environ Health. 2010;9(1):31.","journal-title":"Environ Health"},{"issue":"22","key":"548_CR22","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1093\/jnci\/djs411","volume":"104","author":"AR Schnatter","year":"2012","unstructured":"Schnatter AR, Glass DC, Tang G, Irons RD, Rushton L. Myelodysplastic syndrome and benzene exposure among petroleum workers: an international pooled analysis. J Natl Cancer Inst. 2012;104(22):1724\u201337.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"548_CR23","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/sj.leu.2402798","volume":"17","author":"JH Lee","year":"2003","unstructured":"Lee JH, Lee JH, Shin YR, Lee JS, Kim WK, Chi HS, et al. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia. 2003;17(2):305\u201313.","journal-title":"Leukemia"},{"issue":"3","key":"548_CR24","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.7314\/APJCP.2016.17.3.1535","volume":"17","author":"S Sultan","year":"2016","unstructured":"Sultan S, Irfan SM. Adult primary myelodysplastic syndrome: experience from a tertiary care center in Pakistan. Asian Pac J Cancer Prev APJCP. 2016;17(3):1535\u20137.","journal-title":"Asian Pac J Cancer Prev APJCP"},{"issue":"7","key":"548_CR25","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00277-013-1712-6","volume":"92","author":"C Avgerinou","year":"2013","unstructured":"Avgerinou C, Alamanos Y, Zikos P, Lampropoulou P, Melachrinou M, Labropoulou V, et al. The incidence of myelodysplastic syndromes in Western Greece is increasing. Ann Hematol. 2013;92(7):877\u201387.","journal-title":"Ann Hematol"},{"issue":"5","key":"548_CR26","doi-asserted-by":"crossref","first-page":"589","DOI":"10.47102\/annals-acadmedsg.V33N5p589","volume":"33","author":"LG Lau","year":"2004","unstructured":"Lau LG, Chng WJ, Liu TC, Tan LK, Ong KH, Mow BM, et al. Clinico-pathological analysis of myelodysplastic syndromes according to French\u2013American\u2013British classification and international prognostic scoring system. Ann Acad Med Singap. 2004;33(5):589\u201395.","journal-title":"Ann Acad Med Singap"},{"issue":"13","key":"548_CR27","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.1182\/blood-2007-03-082404","volume":"110","author":"D Haase","year":"2007","unstructured":"Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385\u201395.","journal-title":"Blood"},{"issue":"9","key":"548_CR28","first-page":"632","volume":"24","author":"A Rashid","year":"2014","unstructured":"Rashid A, Khurshid M, Shaikh U, Adil S. Chromosomal abnormalities in primary myelodysplastic syndrome. J Coll Phys Surg-Pak JCPSP. 2014;24(9):632\u20135.","journal-title":"J Coll Phys Surg-Pak JCPSP"},{"issue":"9","key":"548_CR29","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.leukres.2008.11.021","volume":"33","author":"L Li","year":"2009","unstructured":"Li L, Liu XP, Nie L, Yu MH, Zhang Y, Qin TJ, et al. Unique cytogenetic features of primary myelodysplastic syndromes in Chinese patients. Leuk Res. 2009;33(9):1194\u20138.","journal-title":"Leuk Res"},{"issue":"12","key":"548_CR30","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.leukres.2008.05.002","volume":"32","author":"A Gmidene","year":"2008","unstructured":"Gmidene A, Sennana H, Fenaux P, Laatiri A, Zarrouk M, Bouaziz H, et al. Cytogenetic abnormalities in Tunisian de novo myelodysplastic syndrome: a comparison with other populations. Leuk Res. 2008;32(12):1824\u20139.","journal-title":"Leuk Res"},{"issue":"2","key":"548_CR31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0165-4608(94)90094-9","volume":"78","author":"V Parlier","year":"1994","unstructured":"Parlier V, van Melle G, Beris P, Schmidt PM, Tobler A, Haller E, et al. Hematologic, clinical, and cytogenetic analysis in 109 patients with primary myelodysplastic syndrome. Prognostic significance of morphology and chromosome findings. Cancer Genet Cytogenet. 1994;78(2):219\u201331.","journal-title":"Cancer Genet Cytogenet"},{"issue":"22","key":"548_CR32","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","volume":"122","author":"E Papaemmanuil","year":"2013","unstructured":"Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616\u201327.","journal-title":"Blood"},{"issue":"6","key":"548_CR33","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1182\/blood-2006-01-030643","volume":"109","author":"EM Sloand","year":"2007","unstructured":"Sloand EM, Pfannes L, Chen G, Shah S, Solomou EE, Barrett J, et al. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. Blood. 2007;109(6):2399\u2013405.","journal-title":"Blood"},{"key":"548_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13039-016-0223-2","volume":"9","author":"HH Heng","year":"2016","unstructured":"Heng HH, Regan SM, Liu G, Ye CJ. Why it is crucial to analyze non clonal chromosome aberrations or NCCAs? Mol Cytogenet. 2016;9:15.","journal-title":"Mol Cytogenet"},{"key":"548_CR35","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13039-019-0458-9","volume":"12","author":"O Imataki","year":"2019","unstructured":"Imataki O, Kubo H, Takeuchi A, Uemura M, Kadowaki N. Nonclonal chromosomal alterations and poor survival in cytopenic patients without hematological malignancies. Mol Cytogenet. 2019;12:46.","journal-title":"Mol Cytogenet"}],"container-title":["Molecular Cytogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13039-021-00548-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13039-021-00548-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13039-021-00548-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T12:29:33Z","timestamp":1699014573000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularcytogenetics.biomedcentral.com\/articles\/10.1186\/s13039-021-00548-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,8]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["548"],"URL":"https:\/\/doi.org\/10.1186\/s13039-021-00548-z","relation":{},"ISSN":["1755-8166"],"issn-type":[{"value":"1755-8166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,8]]},"assertion":[{"value":"1 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was signed prior to participation in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}